Sorva R, Tähtelä R, Turpeinen M, Juntunen-Backman K, Haahtela T, Risteli L, Risteli J, Sorva A
Department of Allergic Diseases, Helsinki University Central Hospital, Finland.
Acta Paediatr. 1996 Oct;85(10):1176-80. doi: 10.1111/j.1651-2227.1996.tb18224.x.
We evaluated serum and urinary markers of bone turnover in 14 children with asthma during inhaled budesonide and nedocromil treatments. Both the markers of formation (serum carboxy- and amino-terminal propeptides of type I procollagen and serum osteocalcin) and the markers of degradation (serum carboxy-terminal telopeptide of type I collagen and urinary pyridinium cross-links) decreased (p < 0.05) during budesonide treatment for 6 months. During inhaled nedocromil treatment (for the following 6 months), the markers returned to the normal levels. These transient decreases in the markers of both formation and degradation of bone suggest that inhaled budesonide may slightly decrease the bone turnover rate. However, normal "coupling" between formation and degradation seemed to operate, e.g. a change in one resulted in a corresponding change in the other, so that net bone loss did not necessarily occur.
我们评估了14名哮喘儿童在吸入布地奈德和奈多罗米治疗期间的血清和尿液骨转换标志物。在布地奈德治疗6个月期间，形成标志物（血清I型前胶原羧基末端和氨基末端前肽以及血清骨钙素）和降解标志物（血清I型胶原羧基末端肽和尿吡啶交联物）均下降（p<0.05）。在吸入奈多罗米治疗期间（接下来的6个月），这些标志物恢复到正常水平。骨形成和降解标志物的这些短暂下降表明，吸入布地奈德可能会轻微降低骨转换率。然而，形成和降解之间正常的“耦合”似乎起作用，例如一个的变化会导致另一个相应的变化，因此不一定会发生净骨质流失。
